World's Best Scientists 2026 revealed!
Dani P. Bolognesi

Dani P. Bolognesi

D-Index & Metrics

Immunology

D-Index
80
Citations
26991
World Ranking
1612
National Ranking
804

Medicine

D-Index
80
Citations
27085
World Ranking
16998
National Ranking
8525

Dani P. Bolognesi publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Dani P. Bolognesi sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 285 publications — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Dani P. Bolognesi D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Dani P. Bolognesi sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 80 D-Index — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Dani P. Bolognesi is affiliated with Duke University in the United States. Their research centers on molecular biology, genetics, and medicine, with particular attention to cancer research and biotechnology.

The scientist's recent publication record includes four papers spanning from 2021 to 2023. These papers appear in notable journals and cover topics related to glioma diagnosis and treatment as well as cancer immunotherapy. The titles and publication details are:

  • Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy, 2021, Nature Communications
  • Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial, 2023, The Lancet Child & Adolescent Health
  • 48th Annual Meeting of the International Society for Pediatric Neurosurgery, 2022, Child s Nervous System
  • CTIM-15. RESULTS OF A PHASE IB TRIAL OF RECOMBINANT POLIO:RHINOVIRUS IMMUNOTHERAPY FOR RECURRENT PEDIATRIC HIGH GRADE GLIOMA, 2022, Neuro-Oncology

Their work primarily situates within the intersection of these main fields of study:

  • Biochemistry, Genetics and Molecular Biology
  • Medicine

More specifically, their research subfields include:

  • Genetics
  • Cancer Research
  • Molecular Biology
  • Oncology
  • Biotechnology

Major topics in their research portfolio include:

  • Glioma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • MicroRNA in disease regulation
  • Cancer-related molecular mechanisms research
  • RNA Research and Splicing
  • Virus-based gene therapy research
  • RNA Interference and Gene Delivery

Dani P. Bolognesi frequently collaborates with a set of coauthors, who have contributed to multiple works alongside them. These collaborators are:

  • Matthias Gromeier
  • Annick Desjardins
  • Henry S. Friedman
  • Roger E. McLendon
  • David M. Ashley

The common publication venues for Dani P. Bolognesi include:

  • Nature Communications
  • The Lancet Child & Adolescent Health
  • Neuro-Oncology
  • Child s Nervous System

Best Publications

  • 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

    H Mitsuya;K J Weinhold;P A Furman;M H St Clair

  • Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

    P A Furman;J A Fyfe;M H St Clair;K Weinhold

  • POTENT SUPPRESSION OF HIV-1 REPLICATION IN HUMANS BY T-20, A PEPTIDE INHIBITOR OF GP41-MEDIATED VIRUS ENTRY

    J M Kilby;S Hopkins;T M Venetta;B DiMassimo

  • ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX

    Robert Yarchoan;Kent J. Weinhold;H. Kim Lyerly;Edward Gelmann

  • Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein

    K Javaherian;A J Langlois;C McDanal;K L Ross

  • Recurrent glioblastoma treated with recombinant poliovirus

    Annick Desjardins;Matthias Gromeier;James E. Herndon;Nike Beaubier

  • A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

    Carl Wild;Terrence Oas;Charlene McDanal;Dani Bolognesi

  • Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides

    Thomas J. Palker;Michael E. Clark;Alphonse J. Langlois;Thomas J. Matthews

  • Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

    Tom Matthews;Miklos Salgo;Michael Greenberg;Jain Chung

  • Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1

    Kashi Javaherian;Alphonse J. Langlois;Greg J. Larosa;Albert T. Profy

  • Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 in Primary Infection and Long-Term-Nonprogressive Infection

    Alice K. Pilgrim;Giuseppe Pantaleo;Oren J. Cohen;Lisa M. Fink

  • A proposed nomenclature for the virion proteins of oncogenic RNA viruses

    J.T August;Dani P Bolognesi;Erwin Fleissner;Raymond V Gilden

  • Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody

    W G Robey;L O Arthur;T J Matthews;A Langlois

  • Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

    M A Skinner;A J Langlois;C B McDanal;J S McDougal

  • Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack

    H K Lyerly;T J Matthews;A J Langlois;D P Bolognesi

  • Evidence for human infection with an HTLV III/LAV-like virus in Central Africa, 1959.

    A.J. Nahmias;J. Weiss;X. Yao;F. Lee

  • Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion

    T J Matthews;K J Weinhold;H K Lyerly;A J Langlois

  • Clade B-Based HIV-1 Vaccines Elicit Cross-Clade Cytotoxic T Lymphocyte Reactivities in Uninfected Volunteers

    Guido Ferrari;Will Humphrey;M. Juliana McElrath;Jean–Louis Excler

  • Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

    T J Matthews;A J Langlois;W G Robey;N T Chang

  • Assembly of type C oncornaviruses: a model.

    DP Bolognesi;RC Montelaro;H Frank;W Schafer

Frequent Co-Authors

Kent J. Weinhold
Kent J. Weinhold Duke University
Peter J. Fischinger
Peter J. Fischinger National Institutes of Health
Robert C. Gallo
Robert C. Gallo University of South Florida
James N. Ihle
James N. Ihle St. Jude Children's Research Hospital
Heinz Schwarz
Heinz Schwarz Max Planck Society
Barton F. Haynes
Barton F. Haynes Duke University
Thomas J. Matthews
Thomas J. Matthews University of Birmingham
Darell D. Bigner
Darell D. Bigner Duke University
Chin Ho Chen
Chin Ho Chen Duke University
John Bartlett
John Bartlett Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their expertise beyond immunology, pursuing advanced nursing degrees can be a valuable option. Many professionals explore pathways such as the fnp to acnp bridge program online, which allows Family Nurse Practitioners to transition into Acute Care Nurse Practitioners through flexible, specialized coursework.

Accelerated programs are also popular for those looking to enter the healthcare field quickly or advance their careers. Students can consider accelerated np programs designed to fast-track their path to becoming Nurse Practitioners. These programs are often tailored for working professionals seeking efficient, high-quality education.

Non-nurses aiming to join the nursing profession may find online accelerated nursing programs for non nurses particularly useful. These programs provide comprehensive training and credentials in an online format, helping to meet the growing demand for qualified nurses.

Salary expectations are also a crucial consideration. Understanding how much do dnp nurses make can help prospective students evaluate the return on investment for doctoral nursing degrees and plan their career trajectory accordingly.

Best Scientists Citing Dani P. Bolognesi

Trending Scientists

Recently Published Articles